» Articles » PMID: 12649059

Asymptomatic Sexually Transmitted Diseases: the Case for Screening

Overview
Journal Prev Med
Specialty Public Health
Date 2003 Mar 22
PMID 12649059
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The United States has the highest prevalence of sexually transmitted diseases in the developed world. Control strategies should address the most frequent reasons why curable sexually transmitted diseases are not treated.

Methods: We approached 1,631 persons ages 18-29 in various sites and offered them screening for gonorrhea and chlamydial infection and surveys regarding past genitourinary symptoms. For those with past symptoms we abstracted medical records or conducted additional interviews. From these data we estimated the total number of persons who had gonorrhea or chlamydial infections in the previous year, the proportion treated, and the primary reasons for nontreatment.

Results: The prevalence of gonorrhea was 2.3% and that of chlamydial infection was 10.1%. We estimate that 45 and 77% of all cases of gonorrhea and chlamydial infection, respectively, were never symptomatic and that 86 and 95% of untreated cases of gonorrhea and chlamydial infection, respectively, were untreated because they were never symptomatic. The remaining 14 and 5% of untreated cases of gonorrhea and chlamydia, respectively, were not treated because persons did not receive medical care for symptoms.

Conclusions: The primary reason that gonorrhea and chlamydial infections are untreated is that infected persons never have symptoms. The most effective method to control these sexually transmitted diseases is routine screening at high-volume sites.

Citing Articles

Pathogenic and Protective Roles of Neutrophils in Infection.

Wilton Z, Jamus A, Core S, Frietze K Pathogens. 2025; 14(2).

PMID: 40005489 PMC: 11858174. DOI: 10.3390/pathogens14020112.


A VCG-Based Multiepitope Vaccine Incorporating the Cholera Toxin A1 Subunit (MECA) Confers Protective Immunity Against Transcervical Challenge.

Medhavi F, Tanner T, Richardson S, Lundy S, Omosun Y, Eko F Biomedicines. 2025; 13(2).

PMID: 40002702 PMC: 11852492. DOI: 10.3390/biomedicines13020288.


Development of a New Rapid Simultaneous Molecular Assay for the Detection of STI Pathogens and Drug Resistance-Associated Mutations.

Michibuchi M, Yoshikane T, Matsuba Y, Yamazaki T, Hatakeyama S, Takanashi M Mol Diagn Ther. 2025; 29(2):263-272.

PMID: 39820941 PMC: 11861231. DOI: 10.1007/s40291-024-00769-z.


impairs T cell priming by inducing dendritic cell death.

Mao H, Dumas E, Starnbach M Infect Immun. 2025; 93(2):e0040224.

PMID: 39772728 PMC: 11834465. DOI: 10.1128/iai.00402-24.


Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.

Poston T, Girardi J, Kim M, Zwarycz P, Polson A, Yount K Vaccine. 2024; 43(Pt 1):126526.

PMID: 39536454 PMC: 11817958. DOI: 10.1016/j.vaccine.2024.126526.